ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

0RB9 Stallergenes Greer Plc

23.40
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Stallergenes Greer Plc LSE:0RB9 London Ordinary Share GB00BZ21RF93 STALLERGENES GREER PLC ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 23.40 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Stallergenes Greer plc Notice of Results

16/08/2018 7:00am

UK Regulatory


Stallergenes Greer (LSE:0RB9)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Stallergenes Greer Charts.
 
TIDM0RB9 
 
 

Stallergenes Greer to Report First Half Financial Results on 29 August 2018

 

Stallergenes Greer (Paris:STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced it will report financial results for the first half of its 2018 fiscal year after the market closes on 29 August 2018. The Company's management will host a live audio webcast of its earnings conference call the following day, 30 August 2018, at 10:30 am London / 11:30am Paris / 5:30 am Boston to discuss the results.

 

Members of the financial community may access the conference through the dial-in information provided on the company's website at http://stallergenesgreer.com/financial-calendar-events. The live audio webcast will be accessible to the general public via the following link: https://edge.media-server.com/m6/go/STAGR_18HY. Participants are asked to connect at least 15 minutes prior to the conference call to register, download and install any necessary audio software.

 

ABOUT STALLERGENES GREER PLC

 

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the US) and Stallergenes SAS (whose registered office is in France).

 

TRADING INFORMATIONName: Stallergenes GreerISIN: GB00BZ21RF93 1 - Ticker: STAGRICB Classification: 4577LEI: 213800CYVZA7GJQEME86Market: Euronext Paris regulated market

 

Additional information is available at http://www.stallergenesgreer.com.

 

This document (including information incorporated by reference in this document), oral statements made and other information published by the Company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe," "expects," "project," "estimated," "forecast," "should," "plan," "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in the Company's 2017 annual report published on 16 April 2018 on the Company's website www.stallergenesgreer.com. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.

 

Stallergenes GreerCommunications and Investor RelationsNatacha GassenbachTel: +1 (617) 682 2626Email: natacha.gassenbach@stallergenesgreer.comorCaitlin StefanikTel: +1 (857) 331 4117Email: caitlin.stefanik@stallergenesgreer.comorMedia Relations AgencyHavas Paris (Europe)Samuel Rousseau+33 6 77 88 32 43E-mail : samuel.rousseau@havas.comorInvestor Relations AgencyFTI ConsultingArnaud de CheffontainesTel: +33 1 47 03 68 10Email: stalleregenesgreer@fticonsulting.com

 
 
 

View source version on businesswire.com: https://www.businesswire.com/news/home/20180815005056/en/

 
This information is provided by Business Wire 
 
 

(END) Dow Jones Newswires

August 16, 2018 02:00 ET (06:00 GMT)

1 Year Stallergenes Greer Chart

1 Year Stallergenes Greer Chart

1 Month Stallergenes Greer Chart

1 Month Stallergenes Greer Chart

Your Recent History

Delayed Upgrade Clock